D. E. Shaw & Co., Inc. Allogene Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 90,325 shares of ALLO stock, worth $185,166. This represents 0.0% of its overall portfolio holdings.

Number of Shares

90,325

Holding current value

$185,166

% of portfolio

0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.08 - $3.5 $311,854 - $524,755	-149,930 Reduced 62.4%	90,325 $252,000
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $99,183 - $194,809	44,477 Added 22.72%	240,255 $559,000
Q1 2024 May 15, 2024	BUY	$2.92 - $5.63 $350,802 - $676,376	120,138 Added 158.83%	195,778 $875,000
Q4 2023 Feb 14, 2024	SELL	$2.28 - $3.5 $110,803 - $170,093	-48,598 Reduced 39.12%	75,640 $242,000
Q3 2023 Nov 14, 2023	SELL	$3.17 - $5.96 $480,603 - $903,595	-151,610 Reduced 54.96%	124,238 $393,000
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $1.07 Million - $1.6 Million	-236,828 Reduced 46.19%	275,848 $1.37 Million
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $725,754 - $1.21 Million	-147,511 Reduced 22.34%	512,676 $2.53 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $1.24 Million - $2.45 Million	220,492 Added 50.15%	660,187 $4.15 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $1.61 Million - $2.7 Million	156,004 Added 54.99%	439,695 $4.75 Million
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $4.76 Million - $8.61 Million	-701,412 Reduced 71.2%	283,691 $3.23 Million
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $3.48 Million - $6.96 Million	455,288 Added 85.93%	985,103 $8.97 Million
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $6.66 Million - $12.4 Million	507,107 Added 2233.16%	529,815 $7.91 Million
Q3 2021 Nov 15, 2021	SELL	$21.01 - $27.64 $3.77 Million - $4.96 Million	-179,555 Reduced 88.77%	22,708 $584,000
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $4.75 Million - $7.24 Million	202,263 New	202,263 $5.28 Million
Q4 2020 Feb 16, 2021	SELL	$25.24 - $43.45 $163,025 - $280,643	-6,459 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$32.38 - $44.96 $209,142 - $290,396	6,459 New	6,459 $244,000
Q1 2020 May 15, 2020	SELL	$18.22 - $28.25 $2.28 Million - $3.53 Million	-125,030 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$24.82 - $31.4 $3.1 Million - $3.93 Million	125,030 New	125,030 $3.25 Million

Others Institutions Holding ALLO

# of Institutions

162

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $295M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account